Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted…
Name Location Phone Email Amy Henderson, KAM Panhandle 205-215-1926 [email protected] Tom Rice, KAM Jacksonville 603-625-2022 [email protected] Dawn Waldorf, KAM Orlando 386-334-3390 [email protected] Diana Otero, KAM Miami 786-346-4282 [email protected] Rob Blair, KAM Fort Myers 239-281-8278 [email protected] Sarah Trimpe, KAM Tampa 813-731-0981 [email protected] Tiffany Bourne, MSL Southeast 678-895-9621 [email protected] Misty Braun, RBD Southeast 239-293-9601 [email protected] KAM:…
Myovant Sciences and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Myovant’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that…
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company’s flagship product for the treatment of HER2+ metastatic breast cancer was approved by the US Food and Drug Administration in December 2020. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite…
ADC Therapeutics. Confronting cancer with the full potential of our science. ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs. ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Visit…
About Blueprint Medicines Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and…
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform…
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the…
MorphoSys is a clinical stage biopharmaceutical company headquartered in Munich, Germany. MorphoSys is dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed…
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and…
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more. https://www.exelixis.com.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products…
Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the…
© 2021 FLASCO | Premium Website Design by The HDG
